weekly_roundup

BioTechSign Daily Catalyst Roundup - November 12, 2026

Top BioTechSign catalyst names today: KURA, EYPT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 12, 2026

Daily Biotech Catalyst Digest: November 12, 2026

KURA leads the current BioTechSign screen at 86.6/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
KURAKura Oncology, Inc.86.6Apublication signal 100%, clinical activity 100%, short interest 70%
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
NKTRNektar Therapeutics74.4Bpublication signal 100%, short interest 90%, clinical activity 75%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%

Recent Grade-Change Queue

  • EYPT (EyePoint, Inc.) currently grades A with a 84.2/100 catalyst score. Main inputs: clinical activity 100%, short interest 70%, dilution risk 43%.
  • UCBNV (UCB SA) currently grades F with a 12.5/100 catalyst score. Main inputs: clinical activity 12%.
  • SNY (Sanofi SA) currently grades F with a 7.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 12%, short interest 10%.
  • PBYI (Puma Biotechnology Inc) currently grades D with a 48.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, short interest 50%.
  • EXEL (Exelixis Inc) currently grades F with a 27.4/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, clinical activity 29%.
  • TARA (Protara Therapeutics, Inc. ) currently grades F with a 20.4/100 catalyst score. Main inputs: short interest 50%, dilution risk 35%, clinical activity 12%.
  • CMPX (Compass Therapeutics, Inc.) currently grades C with a 52.5/100 catalyst score. Main inputs: short interest 90%, publication signal 60%, clinical activity 50%.
  • BCAX (Bicara Therapeutics Inc.) currently grades F with a 24.8/100 catalyst score. Main inputs: short interest 70%, dilution risk 33%, publication signal 30%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.